InterventionsHumans

Reduction of the 10-Year ASCVD Risk in Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg in Routine Clinical Care—A Real-World Study

ADA Scientific Sessions 2025 Abstract

The paper

RUSEVA A, BASSAN ME, DU EX et al.

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 1734-P

doi.org/10.2337/db25-1734-p

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026